LaNova Medicines Reports the Commencement of P-I Study Evaluating LM-299 for Solid Tumors and Completes Series C1 Financing Round
Shots:
- LaNova Medicines has begun P-I trial of LM-299 (anti-PD-1/VEGF BsAb) to treat solid tumors in Chinese patients, with a plan to commence the same across the US post IND submission anticipated during H2’24
- In addition, the company has secured $42M in series C1 financing led by Sino Biopharmaceuticals with participation from Pudong Innovation Investment, Zhangjiang Haoheng, Qiming Venture Partners & Shanghai Healthcare Capital. It has also started series C2 financing round
- The funding will be utilized to develop LM-299, LM-302 (anti-CLDN 18.2 ADC), in P-III China study in gastric cancer patients with P-II US study planned in H2’25 and LM-108 (anti-CCR8 mAb), in P-II China study for solid tumors with P-II US study planned in H2’24
Ref: PRNewswire | Image: LaNova Medicines
Related News:- LaNova Medicines Entered into an Exclusive License Agreement with AstraZeneca for LM-305 to Treat Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
